Advertisement

Not only volumes matter for breast radiation therapy

  • Orit Kaidar-Person
    Affiliations
    Breast Cancer Radiation Therapy Unit, Sheba Medical Center, Ramat Gan, Israel

    Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel1

    Department of Radiation Oncology (Maastro), GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, The Netherlands
    Search for articles by this author
  • Oreste Gentilini
    Affiliations
    Breast Surgery, San Raffaele University and Research Hospital, Milan, Italy
    Search for articles by this author
  • Philip Poortmans
    Correspondence
    Corresponding author at: Iridium Netwerk, Oosterveldlaan 22, University of Antwerp, Faculty of Medicine and Health Sciences, Campus Drie Eiken, Building S, Universiteitsplein 1, 2610 Wilrijk-Antwerp, Belgium.
    Affiliations
    Department of Radiation Oncology, Iridium Netwerk, Antwerp 2610, Belgium

    University of Antwerp, Faculty of Medicine and Health Sciences, Antwerp, Belgium
    Search for articles by this author
Published:November 02, 2022DOI:https://doi.org/10.1016/j.radonc.2022.10.021
      In contrast to most other indications in radiation oncology, many adhere to field-based techniques based on bony landmarks for breast cancer radiation therapy (RT), representing approximately 25% of the department’s workload [
      • Borras J.M.
      • Barton M.
      • Grau C.
      • Corral J.
      • Verhoeven R.
      • Lemmens V.
      • et al.
      The impact of cancer incidence and stage on optimal utilization of radiotherapy: Methodology of a population based analysis by the ESTRO-HERO project.
      ]. Similarly, the boost volume often is considered erroneously as the “surgical bed” including visible surgical changes, without full understanding of the “tumour bed” concept, often leading to excessively large boost volumes. Therefore, the analysis by Thomsen et al., of the relation between breast induration grade 2–3 at 3 years after RT and the irradiated breast volume, using the data from the Danish Breast Cancer Group (DBCG) phase III prospective trial comparing whole breast irradiation (WBI) with partial breast irradiation (PBI) [
      • Offersen B.V.
      • Alsner J.
      • Nielsen H.M.
      • Jakobsen E.H.
      • Nielsen M.H.
      • Stenbygaard L.
      • et al.
      Partial breast irradiation versus whole breast irradiation for Early breast cancer patients in a randomized Phase III Trial: The Danish breast cancer group partial breast irradiation trial.
      ] [cite as additional reference: Thomsen et al, Radiother Oncol 2022] is extremely relevant.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Radiotherapy and Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Borras J.M.
        • Barton M.
        • Grau C.
        • Corral J.
        • Verhoeven R.
        • Lemmens V.
        • et al.
        The impact of cancer incidence and stage on optimal utilization of radiotherapy: Methodology of a population based analysis by the ESTRO-HERO project.
        Radiother Oncol. 2015; 116: 45-50
        • Offersen B.V.
        • Alsner J.
        • Nielsen H.M.
        • Jakobsen E.H.
        • Nielsen M.H.
        • Stenbygaard L.
        • et al.
        Partial breast irradiation versus whole breast irradiation for Early breast cancer patients in a randomized Phase III Trial: The Danish breast cancer group partial breast irradiation trial.
        J Clin Oncol. 2022; (Jco2200451)
        • Kaidar-Person O.
        • Meattini I.
        • Zippel D.
        • Poortmans P.
        Apples and oranges: comparing partial breast irradiation techniques.
        Rep Pract Oncol Radiother. 2020; 25: 780-782
        • Kaidar-Person O.
        • Fortpied C.
        • Hol S.
        • Weltens C.
        • Kirkove C.
        • Budach V.
        • et al.
        The association of internal mammary and medial supraclavicular lymph node radiation technique with clinical outcomes: Results from the EORTC 22922/10925 randomised trial.
        Radiother Oncol. 2022; 172: 99-110
        • Offersen B.V.
        • Alsner J.
        • Nielsen H.M.
        • Jakobsen E.H.
        • Nielsen M.H.
        • Krause M.
        • et al.
        Hypofractionated versus standard fractionated radiotherapy in patients with early breast Cancer or ductal carcinoma in situ in a randomized Phase III Trial: The DBCG HYPO trial.
        J Clin Oncol. 2020; (JCO .20.01363)
        • Meattini I.
        • Becherini C.
        • Boersma L.
        • Kaidar-Person O.
        • Marta G.N.
        • Montero A.
        • et al.
        European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer.
        Lancet Oncol. 2022; 23: e21-e31
        • Kaidar-Person O.
        • Offersen B.V.
        • Boersma L.
        • Meattini I.
        • Dodwell D.
        • Wyld L.
        • et al.
        Tricks and tips for target volume definition and delineation in breast cancer: Lessons learned from ESTRO breast courses.
        Radiother Oncol. 2021; 162: 185-194
        • Finnegan R.
        • Lorenzen E.L.
        • Dowling J.
        • Jensen I.
        • Berg M.
        • Thomsen M.S.
        • et al.
        Analysis of cardiac substructure dose in a large, multi-centre danish breast cancer cohort (the DBCG HYPO trial): Trends and predictive modelling.
        Radiother Oncol. 2020; 153: 130-138
        • Borger J.H.
        • Kemperman H.
        • Smitt H.S.
        • Hart A.
        • van Dongen J.
        • Lebesque J.
        • et al.
        Dose and volume effects on fibrosis after breast conservation therapy.
        Int J Radiat Oncol Biol Phys. 1994; 30: 1073-1081
        • Collette S.
        • Collette L.
        • Budiharto T.
        • Horiot J.C.
        • Poortmans P.M.
        • Struikmans H.
        • et al.
        Predictors of the risk of fibrosis at 10 years after breast conserving therapy for early breast cancer: a study based on the EORTC Trial 22881–10882 'boost versus no boost'.
        Eur J Cancer. 2008; 44: 2587-2599
        • Brouwers P.
        • van Werkhoven E.
        • Bartelink H.
        • Fourquet A.
        • Lemanski C.
        • van Loon J.
        • et al.
        Predictors for poor cosmetic outcome in patients with early stage breast cancer treated with breast conserving therapy: Results of the Young boost trial.
        Radiother Oncol. 2018; 128: 434-441
        • Coles C.E.
        • Griffin C.L.
        • Kirby A.M.
        • Titley J.
        • Agrawal R.K.
        • Alhasso A.
        • et al.
        Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial.
        Lancet. 2017; 390: 1048-1060
        • Meattini I.
        • Poortmans P.M.P.
        • Marrazzo L.
        • Desideri I.
        • Brain E.
        • Hamaker M.
        • et al.
        Exclusive endocrine therapy or partial breast irradiation for women aged >/=70 years with luminal A-like early stage breast cancer (NCT04134598 - EUROPA): Proof of concept of a randomized controlled trial comparing health related quality of life by patient reported outcome measures.
        J Geriatr Oncol. 2021; 12: 182-189
        • Tsang Y.
        • Ciurlionis L.
        • Kirby A.M.
        • Locke I.
        • Venables K.
        • Yarnold J.R.
        • et al.
        Clinical impact of IMPORT HIGH trial (CRUK/06/003) on breast radiotherapy practices in the United Kingdom.
        Br J Radiol. 2015; 88: 20150453
        • Strnad V.
        • Hannoun-Levi J.M.
        • Guinot J.L.
        • Lössl K.
        • Kauer-Dorner D.
        • Resch A.
        • et al.
        Recommendations from GEC ESTRO Breast Cancer Working Group (I): Target definition and target delineation for accelerated or boost Partial Breast Irradiation using multicatheter interstitial brachytherapy after breast conserving closed cavity surgery.
        Radiother Oncol. 2015; 115: 342-348
        • Aznar M.C.
        • Meattini I.
        • Poortmans P.
        • Steyerova P.
        • Wyld L.
        To clip or not to clip. That is no question!.
        Eur J Surg Oncol. 2017; 43: 1145-1147

      Linked Article